Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder), Ocular Hypertension, Ocular Hypertension (OH), Ocular Hypertension Glaucoma, IOP, Intraocular Pressure, Glaucoma Open-Angle, Glaucoma and Ocular Hypertension, Glaucoma Patients and Healthy Controls, Normal Tension Glaucoma (NTG)
Interventions
miLens system
Device
Lead sponsor
Smartlens, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Fullerton, California • Petaluma, California • Torrance, California
Conditions
Normal Tension Glaucoma, Obstructive Sleep Apnea
Interventions
Clinical observation, diagnostic testing
Other
Lead sponsor
Northwell Health
Other
Eligibility
21 Years and older
Enrollment
100 participants
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Not yet recruiting Not applicable Interventional

DSLT in Normal Tension Glaucoma (NTG) Asian Eyes

NCT07300852
Conditions
Normal Tension Glaucoma (NTG), Glaucoma, Open Angle Glaucoma (OAG), Glaucoma, Open Angle
Interventions
Direct Selective Laser Trabeculoplasty (DSLT)
Device
Lead sponsor
Ngoc Nguyen Inc.
Other
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Jose, California
Completed No phase listed Observational Accepts healthy volunteers

EVALUATION of CATS TONOMETER PRISM in LASIK SUBJECTS

NCT06266351
Conditions
Glaucoma, Ocular Hypertension, Normal Tension Glaucoma
Interventions
This is observational IOP measurement
Device
Lead sponsor
Intuor Technologies, Inc.
Industry
Eligibility
22 Years and older
Enrollment
198 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Tucson, Arizona • Memphis, Tennessee
Conditions
Normal Tension Glaucoma (NTG)
Interventions
QLS-101, Timolol maleate PF 0.5% ophthalmic solution
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Conditions
Glaucoma, Open Angle
Interventions
brimonidine, timolol
Drug
Lead sponsor
Chicago Center for Vision Research
Other
Eligibility
30 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
12
States / cities
Little Rock, Arkansas • Gainesville, Florida • Palm Beach Gardens, Florida + 7 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study on Ambulatory Intraocular Pressure and Blood Pressure Monitoring in Glaucoma

NCT01912599
Conditions
Normal-Tension Glaucoma
Interventions
Sensimed Triggerfish, Blood Pressure
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Normal Tension Glaucoma
Interventions
Netarsudil Ophthalmic, Bimatoprost Ophthalmic
Drug
Lead sponsor
Salus University
Other
Eligibility
21 Years to 89 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Vestal, New York
Not yet recruiting Phase 1Phase 2 Interventional

Topical Insulin for Glaucoma (TING2)

NCT07619482
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Glaucoma; Drugs, Normal Tension Glaucoma, Primary Open-angle Glaucoma
Interventions
Timolol Maleate, Brimonidine Tartrate
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Normal Tension Glaucoma
Interventions
Gingko Baloba, Placebo
Dietary Supplement · Other
Lead sponsor
Robert Ritch, MD, LLC.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Normal Tension Glaucoma
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Completed No phase listed Observational Accepts healthy volunteers

Will Listening to Music Make it Easier to Take a Visual Field Test?

NCT01027039
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Glaucoma
Interventions
brimonidine 0.15%
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
35 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Primary Open Angle Glaucoma, Low Tension Glaucoma, Cataract, Ocular Hypertension
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Phase 4 Interventional Accepts healthy volunteers

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

NCT06449352
Conditions
Normal Tension Glaucoma
Interventions
Netarsudil, Brimonidine
Drug
Lead sponsor
Westlake Eye Specialists
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Austin, Texas • Killeen, Texas • Kyle, Texas + 1 more
Conditions
Open Angle Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
45 Years to 85 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
Interventions
QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Normal Tension Glaucoma
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 101 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
New York, New York